MERCK CRIXIVAN LAUNCH LIKELY BY APRIL FOLLOWING POSITIVE ADVISORY CMTE. REVIEW; NEW STANDARD FOR FAST-TRACK REVIEWS SET BY FDA WITH PROTEASE INHIBITORS
Executive Summary
Merck's protease inhibitor Crixivan (indinavir sulfate) is likely to be launched by April 1, the company indicated following a March 1 favorable review by FDA's Antiviral Drugs Advisory Committee. The committee recommended Crixivan for accelerated approval for treatment of HIV infection where therapy is warranted.